Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
Regulatory

Bausch + Lomb Receives FDA 510(k) Clearance for Bi-Blade+(TM) Dual-Port Vitrectomy Cutter and Adaptive Fluidics(TM) Advanced Update

FDA clearance lifts Bausch + Lomb’s surgical toolkit, but market impact stays modest

By The Northwire Desk — AI Analysis Apr 08, 2026 · 07:00 BLCO · 22.15 BAUSCH + LOMB CORPORATION
Executive Summary
  • The U.S. Food and Drug Administration issued a 510(k) clearance for the Bi‑Blade+ dual‑port vitrectomy cutter and its accompanying Adaptive Fluidics software update on the Stellaris Elite Vision Enhancement System.
  • Technical improvements: cutting speed ↑ to 25,000 cpm (vs 15,000 cpm), flow rate +≈25%, cutter vibration –62%, infusion pressure –62% with Adaptive Fluidics, and intra‑ocular pressure stability within 10‑20 mmHg.
  • The clearance applies only to Bausch + Lomb’s Stellaris Elite platform equipped with the new procedure packs.
Material Impact
  • Scope: A regulatory clearance for an incremental hardware/software upgrade. No new indication, no major market expansion, and the product is already in commercial use (Stellaris Elite).
  • Market expectation: The clearance was anticipated; Bausch + Lomb had previously announced upcoming FDA filings for Bi‑Blade+. Hence the news confirms expectations rather than surprises.
  • Revenue effect: Incremental sales uplift expected from existing Stellaris customers upgrading to Bi‑Blade+ packs and from new adopters attracted by performance gains. The impact is likely a modest double‑digit percentage increase in surgical device revenue on a low‑single‑digit absolute dollar basis (Surgical segment was $894 M FY2025).
  • Risk: Limited to the product’s compatibility – only works with Stellaris Elite systems, capping addressable market. No change to royalty structure or pricing disclosed.

Conclusion: The announcement is a routine positive development; it validates the pipeline and may modestly boost short‑term surgical revenue but does not constitute a material catalyst.

BLCO · Price
Company Overview

Bausch + Lomb is a global leader in eye health, operating across three segments: Vision Care (contact lenses & OTC products), Surgical (intra‑ocular lenses, vitrectomy cutters, laser platforms), and Pharmaceuticals (dry‑eye, ocular inflammation).
Flagship surgical platform: Stellaris Elite Vision Enhancement System, now upgraded with Bi‑Blade+ cutter and Adaptive Fluidics.

Read the original news release →

More from BAUSCH + LOMB CORPORATION

Jul 01, 2026 · 07:00

Dry Eye Survey Reinforces Premium Pricing Power, But Lacks Catalyst to Break Recent Consolidation

Other Jun 01, 2026 · 06:59

Bausch + Lomb Expands Dry Eye Portfolio with Preservative-Free Blink Launch; Execution on $7B Pipeline Continues Amid Margin Expansion

Financings May 19, 2026 · 07:00

Bausch + Lomb Executes H1 2026 Launch Plan Amidst Margin Expansion Push

Other May 07, 2026 · 07:00

Bausch + Lomb Expands Surgical Portfolio with European Bi-Blade+ Launch Amidst Guidance Raise

Other May 06, 2026 · 07:15

Bausch + Lomb Pipeline Webinar Confirms Long-Term Growth Narrative, But Near-Term Surgical Headwinds Persist Despite Q1 Guidance Raise

Other Apr 30, 2026 · 07:00

Bausch + Lomb Pipeline Validation Follows Q1 Guidance Raise Amidst Margin Expansion

Other